食管与食管胃接合处癌工作步骤NCCN指南2016v1-2
2018年07月27日 6821人阅读 返回文章列表
HISTOLOGY
CLINICAL STAGE山东省肿瘤医院呼吸肿瘤内科张品良
ADDITIONAL EVALUATION (as clinically indicated)
Squamous cell carcinoma
Stage I–III (locoregional disease)
* Multidisciplinary evaluation
▲Consider nasogastric or J-tube (preferred) or PEG for preoperative nutritional support
Medically fit for surgery
See ESOPH-3
Non-surgical candidate
See ESOPH-8
组织学
临床分期
其他评估(根据临床指征)
鳞癌
I–III期(局部区域病变)
*多学科评估
▲对于术前营养支持,考虑鼻饲或J型管(首选)或聚乙二醇(PEG)
医学上适合手术
见ESOPH-3
非手术候选者
见ESOPH-8
HISTOLOGY
TUMOR CLASSIFICATION
PRIMARY TREATMENT OPTIONS FOR MEDICALLY FIT PATIENTS
Squamous cell carcinoma
pTis
Endoscopic therapies (preferred):
* ER
* Ablation
* ER followed by ablation
Or
Endoscopic surveillance
See ESOPH-A
Esophagectomy
See Surgical Outcomes After Esophagectomy (ESOPH-6)
pT1a
Endoscopic therapies (preferred):
* ER
* ER followed by ablation
or
Endoscopic surveillance
See ESOPH-A
Esophagectomy
See Surgical Outcomes After Esophagectomy (ESOPH-6)
pT1b, N0
Esophagectomy
cT1b, N+
cT2-T4a, N0-N+
See (ESOPH-4)
cT4b
cT1b, N+
cT2-T4a, N0-N+
Preoperative chemoradiation (non-cervical esophagus) (RT, 41.4–50.4 Gy + concurrent chemotherapy)
Or
Definitive chemoradiation (only for patients who decline surgery) (recommended for cervical esophagus) (RT, 50–50.4 Gy + concurrent chemotherapy)
or
See Response Assessment (ESOPH-5)
Esophagectomy (non-cervical esophagus) (T1b-T2 low-risk lesions:<2 cm, well differentiated )
See Surgical Outcomes After Esophagectomy (ESOPH-6)
cT4b
Definitive chemoradiation (RT, 50–50.4 Gy + concurrent chemotherapy)
Consider chemotherapy alone in the setting of invasion of trachea, great vessels, or heart
See Palliative Management (ESOPH-10)
See Response Assessment (ESOPH-5)
组织学
肿瘤分类
医学上适合的患者的初始治疗选择
鳞癌
pTis
内镜治疗(首选):
* 内镜黏膜切除术(ER)
*消融
* 内镜黏膜切除术(ER)然后消融
或
内镜监测
见ESOPH-A
食管切除术
见食管切除术后手术效果(ESOPH-6)
pT1a
内镜治疗(首选):
* 内镜黏膜切除术(ER)
* 内镜黏膜切除术(ER)然后消融
或
内镜监测
见ESOPH-A
食管切除术
见食管切除术后手术效果(ESOPH-6)
pT1bN0
食管切除术
cT1bN+
cT2-T4aN0-N+
见(ESOPH-4)
cT4b
cT1bN+
cT2-T4aN0-N+
术前化放疗(非颈段食管)(RT,41.4–50.4 Gy +同步化疗)
或
根治性化放疗(仅用于拒绝手术的患者)(推荐用于颈段食管)(RT,50–50.4 Gy +同步化疗)
或
见疗效评估
(ESOPH-5)
食管切除术(非颈段食管)(T1b-T2低危病变:< 50px,分化良好的)
见食管切除术后手术效果
(ESOPH-6)
cT4b
根治性化放疗(RT 50-50.4 Gy +同步化疗)
在气管、大血管或心脏侵犯的情况下考虑单纯化疗
见姑息治疗(ESOPH-10)
见疗效评估
(ESOPH-5)
PRIMARY TREATMENT FOR MEDICALLY FIT PATIENTS WITH SQUAMOUS CELL CARCINOMA
RESPONSE ASSESSMENT
OUTCOME
ADDITIONAL MANAGEMENT
Preoperative chemoradiation
* CT scan with contrast (not required if PET/CT is done)
* PET/CT or PET (category 2B)
* Upper GI endoscopy and biopsy (optional if surgery is planned)
No evidence of disease
Esophagectomy
Or
Surveillance (category 2B)
See Follow-up (ESOPH-9)
See Surgical Outcomes After Esophagectomy (ESOPH-7)
Persistent local disease
Esophagectomy (preferred)
or
See Palliative Management (ESOPH-10)
See Surgical Outcomes After Esophagectomy (ESOPH-7)
Unresectable
or
Metastatic disease
See Palliative Management (ESOPH-10)
Definitive chemoradiation
* CT scan with contrast (not required if PET/CT is done)
* PET/CT or PET (category 2B)
* Upper GI endoscopy and biopsy
No evidence of disease
Surveillance
Follow-up (See ESOPH-9)
Persistent local disease
Esophagectomy
or
See Palliative Management
New metastatic disease
See Palliative Management (ESOPH-10)
健康状况适合的鳞状细胞癌患者的初始治疗
疗效评估
结果
其他治疗
术前化放疗
*强化CT扫描(如果做了PET/CT则不需要)
* PET/CT或PET(2B类)
上消化道内窥镜检查与活检(可选择,如果计划手术)
无疾病证据
食管切除术
或
监测(2B类)
见随访
(ESOPH-9)
见食管切除术后手术效果
(ESOPH-7)
顽固性局部病变
食管切除术(首选)
或
见姑息治疗(ESOPH-10)
见食管切除术后手术效果
(ESOPH-7)
不可切除的
或
转移性疾病
见姑息治疗(ESOPH-10)
根治性化放疗
*强化CT扫描(如果做了PET/CT则不需要)
* PET/CT或PET(2B类)
* 上消化道内镜检查与活检
无疾病证据
监测
随访
(见ESOPH-9)
顽固性局部病变
食管切除术
或
见姑息治疗
新发转移性疾病
见姑息治疗(ESOPH-10)